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Tuberculosis represents an important clinical and public health problem globally, particu-
larly in low- and middle-income countries. During the last 20 years, two relevant events
has changed the epidemiology of the disease: the spread of the TB/HIV co-infection and
the emergence and spread of the multi-drug resistance tuberculosis (i.e., tuberculosis
caused by strains resistant to at least isoniazid and rifampicin). The latter phenomenon
has been generated by the inappropriate management of the anti-tuberculosis drugs. Cur-
rently, the World Health Organization estimates at least 600,000 MDR-TB cases worldwide,
particularly in China, India, South Africa, and in former Soviet Union countries. Unfortu-
nately, new difficult-to-treat MDR-TB cases have been described, named XDR- or TDR-TB
(extensively or totally drug-resistant tuberculosis, respectively). Numerous observational
retrospective studies proved the poorer prognostic profile of the MDR-TB cases when
compared with drug-susceptible tuberculosis. The clinical management of the patients
with an XDR and beyond pattern is complicated owing to the poorest, expensive, and toxic
therapeutic options. MDR-TB is currently under-reported because of methodological issues,
mainly related to the poor proficiency of laboratory testing. National public health strate-
gies should reduce the increase of tuberculosis cases without therapeutic alternatives. Fur-
thermore, research and development activities, based on continuous and sustained
funding, should be improved, together with the implementation and the scale-up of effec-
tive infection control measures in healthcare settings and in the community.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Resistance to antibiotics is deemed a man-made phe-
nomenon attributable to the selection of naturally resistant
strains. It is mainly caused by a sub-therapeutic drug
exposure related to an inadequate (drug/regimen selec-
tion/dosage and duration of treatment) antibiotic prescrip-
tion [1–7].
This phenomenon, described for anti-viral, anti-bacterial,
anti-protozoal, and anti-mycotic drugs, can have relevant
clinical and public health consequences, particularly in an
era where research and development activities of the phar-
maceutical companies are focused mainly on chronic-degen-
erative diseases [8].
In the fight against some infectious diseases (for instance,
those caused by Staphylococcus aureus or Escherichia coli infec-
tions), it was described as a sort of ‘back to the future’, that
is, a return to a pre-Fleming period, where the natural history
of the infectious diseases could not be altered [1,2].Tuberculosis, one of the most important contagious
diseases globally, is currently treated with a poli-chemothera-
peutic approach whose efficacy and safety have been fre-
quently argued, particularly in some high-risk groups. Since
the 1950s, it was described as the mono- or poli-resistance of
Mycobacterium tuberculosis isolates to anti-tuberculosis drugs,
and several therapeutic options have been suggested [9,10].
However, since the 1990s, a new epidemiological scenario has
been described with the emergence and spread of pulmonary
and/or extra-pulmonary forms of multi-drug resistant tuber-
culosis, i.e. tuberculosis caused by strains resistant to at least
two of the most effective anti-tuberculosis drugs: isoniazid
and rifampicin [11–15].
Since its first description, it was clear its poorer prognosis
if compared with drug-susceptible tuberculosis and the
necessity to have more efficacious and safer pharmacological
alternatives [11,16–19].
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mainly located in low- and middle-income countries, where
the political, healthcare, and societal roots of this new
epidemiological entity could not be hindered. In 2006 a new,
more serious, resistance pattern was depicted and named
extensively drug-resistant tuberculosis (XDR-TB, that is an
MDR-TB with additional resistances to any fluoroquinolones
and to at least one second-line injectable-amikacin, capreo-
mycin, or kanamycin). Numerous manuscripts and system-
atic reviews summarized its striking negative impact on
clinical outcomes like mortality, treatment success and fail-
ure [20–23]. The recent World Health Organization global re-
port, issued in 2012, pointed out that there were 27 high
MDR-TB burden countries in 2011, with the highest absolute
frequencies in China, India, Russian Federation, and South
Africa, which represent 60% of the total cases. The highest
proportions of new and previously treated MDR-TB patients
were noted in Eastern Europe and Central Asia. MDR- and
XDR-TB have been reported in 135 and 84 countries, respec-
tively, with a best estimated size of 630,000 cases [24].
In 2007 Migliori et al. described the first two cases of tuber-
culosis patients without therapeutic options, because of resis-
tances against first-, second-, and third-line drugs; they used
for the first time the term XXDR for extremely drug-resistant
tuberculosis [25]. Small samples of patients with similar drug
resistance patterns were described in Iran and India and were
named totally drug-resistant tuberculosis (TDR-TB) [26–28].
Actually, there is no agreed-upon definition for cases of
tuberculosis with resistances to all the anti-tuberculosis drug
armamentarium. If the acronyms M/XDR-TB were universally
accepted because of a standardized methodology of the
in vitro susceptibility testing for the case-defining drugs, the
World Health Organization does not give full confidence to
the laboratory evaluation for some of the second- and third-
line drugs. What was proven by a retrospective collection of
several cohorts worldwide is the clinical and operational/pub-
lic health value of a resistance patternmore complicated than
XDR, having a higher risk of treatment failure and death, as
well as a lower likelihood of treatment success,withmore pos-
sibilities ofM. tuberculosis transmission [29,30]. These forms of
disease mimic the natural history of the untreated tuberculo-
sis, evoking the above-mentioned paradigm of ‘‘Drug resis-
tance beyond XDR-TB: back to the future’’ [31].
The recent advertisement in the media of those drug-
resistant forms could be dangerous for the tuberculosis pa-
tients: it should be scientifically driven in order to avoid
new stigmas and racism-like episodes. On the other side, its
knowledge could have a significant impact on the political
world, pushing new public health strategies of continuous
and relevant financing for the healthcare strengthening and
antibiotic stewardship. The epidemiological burden is at this
time relevant, but every political and scientific effort should
be put in place by all the stakeholders to avoid a new dramatic
epidemic which would mainly affect the poorest and most
vulnerable human beings.
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